Edgar Filing: COHEN CHARLES J. - Form 4

COHEN CH Form 4										
March 13, 2								PPROVAL		
FORM	A 4 UNITED		RITIES . ashingtor			E COMMISSION	OMB OMB Number:	3235-0287		
Check th		vv	asinington	I, D.C. 20	0349			January 31,		
if no lon subject t Section Form 4	16.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Expires: 2005 Estimated average burden hours per response 0.5			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						n				
(Print or Type	Responses)									
1. Name and A COHEN C	Symbol	2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XEN			5. Relationship of Reporting Person(s) to Issuer					
(Last)		3. Date of Earliest Transaction			(Check all applicable)					
		(Month/Day/Year)			Director 10% Owner					
	ON CEUTICALS INC IORE WAY	03/12/ C, 200 -	2018			X Officer (give below) V	title Oth below) 'P, Biology	her (specify		
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
BURNABY	Y, A1 V5G 4W8					Form filed by M Person	Iore than One R	Reporting		
(City)	(State)	(Zip) Ta	ble I - Non-	Derivative	e Securities A	Acquired, Disposed of	, or Beneficia	ally Owned		
1.Title of Security (Instr. 3)	Security (Month/Day/Year) Execution Instr. 3) any				(A) or l of (D) 4 and 5) (A) or	SecuritiesFBeneficially(IOwned(I	. Ownership orm: Direct D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Re	port on a separate line	e for each class of se	curities bene	-	-	-				
				inforı requi	nation con red to resp ays a curre	spond to the collec tained in this form a ond unless the forr ntly valid OMB con	are not n	SEC 1474 (9-02)		
	Tab	le II - Derivative Se (e.g., puts, ca				Beneficially Owned securities)				
		saction Date 3A. De /Day/Year) Execut		4. Transact	5. Number tiorDerivative		ble and	7. Title and Amou Underlying Secur		

2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D

Edgar Filing: COHEN CHARLES J. - Form 4

Security (Instr. 3)	5		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)		
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 4.75	03/12/2018		А	40,000	<u>(1)</u>	03/11/2028	Common Shares	40,000	
Reporting Owners										
Reporting Owner Name / Address			Rela	tionships						
		Director	10% Owner	Officer	Other					
COHEN CHARLES J. C/O XENON PHARMACEUTICALS 200 - 3650 GILMORE WAY BURNABY, A1 V5G 4W8		INC	VP, Biology							
Signa	tures									
/s/ Joanne Smartt, Attorney-in-fact 03/13		03/13/2018								
<u>**</u> Signatu	ire of Reporting Per	rson	Date							
Explanation of Responses:										

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vesting 25% on January 1, 2019, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S ()